Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

nuvalent inc - NUVL

NUVL

Close Chg Chg %
105.64 -0.21 -0.20%

Closed Market

105.43

-0.21 (0.20%)

Volume: 992.15K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: nuvalent inc - NUVL

NUVL Key Data

Open

$103.84

 Day Range

102.04 - 106.46

52 Week Range

55.54 - 113.02

 Market Cap

$8.29B

Shares Outstanding

78.62M

 Public Float

51.89M

Beta

1.31

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.85

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

608.51K

  

NUVL Performance

1 Week
 
 9.07%
 
1 Month
 
 6.06%
 
3 Months
 
 4.55%
 
1 Year
 
 60.37%
 
5 Years
 
 N/A
 

NUVL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About nuvalent inc - NUVL

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

NUVL At a Glance

Nuvalent, Inc.
One Broadway
Cambridge, Massachusetts 02142
Phone 1-857-357-7000 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -425,377,000.00
Sector Health Technology Employees 228
Fiscal Year-end 12 / 2026
View SEC Filings

NUVL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 6.304
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -14.336
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

NUVL Efficiency

Revenue/Employee N/A
Income Per Employee -1,865,688.596
Receivables Turnover N/A
Total Asset Turnover N/A

NUVL Liquidity

Current Ratio 15.273
Quick Ratio 15.273
Cash Ratio 15.048

NUVL Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -33.305
Return on Equity -36.70
Return on Total Capital -34.075
Return on Invested Capital -36.70

NUVL Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nuvalent Inc - NUVL

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - -
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - -
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
86.11M 149.49M 280.37M 414.31M
Research & Development
63.73M 113.24M 217.77M 306.97M
Other SG&A
22.38M 36.25M 62.59M 107.34M
SGA Growth
+87.94% +73.61% +87.55% +47.77%
Other Operating Expense
- - - -
-
Unusual Expense
- - 17.94M 55.22M
-
EBIT after Unusual Expense
(86.11M) (149.49M) (298.31M) (469.53M)
Non Operating Income/Expense
4.25M 23.27M 38.32M 44.73M
Non-Operating Interest Income
- 4.25M 23.27M 38.32M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(81.85M) (126.22M) (259.99M) (424.79M)
Pretax Income Growth
-76.65% -54.20% -105.98% -63.39%
Pretax Margin
- - - -
-
Income Tax
- - 764.00K 585.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(81.85M) (126.22M) (260.76M) (425.38M)
Minority Interest Expense
- - - -
-
Net Income
(81.85M) (126.22M) (260.76M) (425.38M)
Net Income Growth
-76.65% -54.20% -106.59% -63.13%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(81.85M) (126.22M) (260.76M) (425.38M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(81.85M) (126.22M) (260.76M) (425.38M)
EPS (Basic)
-1.648 -2.1678 -3.9265 -5.8522
EPS (Basic) Growth
-71.77% -31.54% -81.13% -49.04%
Basic Shares Outstanding
49.67M 58.22M 66.41M 72.69M
EPS (Diluted)
-1.648 -2.1678 -3.9265 -5.8522
EPS (Diluted) Growth
-71.77% -31.54% -81.13% -49.04%
Diluted Shares Outstanding
49.67M 58.22M 66.41M 72.69M
EBITDA
(86.11M) (149.49M) (280.37M) (414.31M)
EBITDA Growth
-87.94% -73.61% -87.55% -47.77%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 143.941
Number of Ratings 19 Current Quarters Estimate -1.408
FY Report Date 06 / 2026 Current Year's Estimate -5.56
Last Quarter’s Earnings -1.265 Median PE on CY Estimate N/A
Year Ago Earnings -5.85 Next Fiscal Year Estimate -4.278
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 17 18 18
Mean Estimate -1.41 -1.41 -5.56 -4.28
High Estimates -1.21 -0.98 -3.93 -2.06
Low Estimate -1.62 -1.74 -6.75 -7.22
Coefficient of Variance -8.72 -14.27 -13.85 -34.62

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 15
OVERWEIGHT 3 3 3
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Nuvalent Inc - NUVL

Date Name Shares Transaction Value
Mar 3, 2026 Deborah Miller Chief Legal Officer 65,134 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.89 per share 448,773.26
Mar 3, 2026 Deborah Miller Chief Legal Officer 62,436 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.64 per share 6,408,431.04
Mar 3, 2026 Deborah Miller Chief Legal Officer 59,834 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.41 per share 6,187,433.94
Mar 3, 2026 Deborah Miller Chief Legal Officer 59,634 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.96 per share 6,199,550.64
Mar 3, 2026 Deborah Miller Chief Legal Officer 89,108 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 Ron Squarer Director 2,837 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 12, 2025 Ron Squarer Director 4,418 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 18, 2025 James R. Porter President and CEO; Director 276,062 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $27.85 per share 7,688,326.70
Apr 18, 2025 James R. Porter President and CEO; Director 265,075 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.31 per share 18,107,273.25
Apr 18, 2025 James R. Porter President and CEO; Director 254,015 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.05 per share 17,539,735.75
Apr 18, 2025 James R. Porter President and CEO; Director 249,550 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.05 per share 17,480,977.50
Apr 18, 2025 James R. Porter President and CEO; Director 249,062 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.73 per share 17,616,155.26
Apr 18, 2025 James R. Porter President and CEO; Director 231,780 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Nuvalent Inc in the News